CPRX Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of -111.65%. Catalyst Pharmaceuticals's return on equity of 29.43% beat Ionis Pharmaceuticals's return on equity of -100.15%.

Catalyst Pharmaceuticals has a consensus price target of $34.29, signalling upside risk potential of 52.52%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $57.66 which suggests that it could grow by 54.12%. Given that Ionis Pharmaceuticals has higher upside potential than Catalyst Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.721, which suggesting that the stock is 27.922% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.182, suggesting its less volatile than the S&P 500 by 81.778%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are larger than Ionis Pharmaceuticals quarterly revenues of $131.6M. Catalyst Pharmaceuticals's net income of $56.7M is higher than Ionis Pharmaceuticals's net income of -$146.9M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 14.32x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.29x versus 7.97x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of -486.44%. Catalyst Pharmaceuticals's return on equity of 29.43% beat Nektar Therapeutics's return on equity of -201.73%.

Catalyst Pharmaceuticals has a consensus price target of $34.29, signalling upside risk potential of 52.52%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.92 which suggests that it could grow by 766.63%. Given that Nektar Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Nektar Therapeutics is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.721, which suggesting that the stock is 27.922% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.552, suggesting its less volatile than the S&P 500 by 44.806%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are larger than Nektar Therapeutics quarterly revenues of $10.5M. Catalyst Pharmaceuticals's net income of $56.7M is higher than Nektar Therapeutics's net income of -$50.9M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 14.32x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.29x versus 1.36x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of -151.35%. Catalyst Pharmaceuticals's return on equity of 29.43% beat Rhythm Pharmaceuticals's return on equity of -116.92%.

Catalyst Pharmaceuticals has a consensus price target of $34.29, signalling upside risk potential of 52.52%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $83.42 which suggests that it could grow by 34.57%. Given that Catalyst Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe Catalyst Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.721, which suggesting that the stock is 27.922% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.301, suggesting its more volatile than the S&P 500 by 130.127%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $32.7M. Catalyst Pharmaceuticals's net income of $56.7M is higher than Rhythm Pharmaceuticals's net income of -$49.5M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 14.32x while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.29x versus 27.96x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Xencor has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of -147.92%. Catalyst Pharmaceuticals's return on equity of 29.43% beat Xencor's return on equity of -32.34%.

Catalyst Pharmaceuticals has a consensus price target of $34.29, signalling upside risk potential of 52.52%. On the other hand Xencor has an analysts' consensus of $28.20 which suggests that it could grow by 230.21%. Given that Xencor has higher upside potential than Catalyst Pharmaceuticals, analysts believe Xencor is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.721, which suggesting that the stock is 27.922% less volatile than S&P 500. In comparison Xencor has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.145%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Xencor pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are larger than Xencor quarterly revenues of $32.7M. Catalyst Pharmaceuticals's net income of $56.7M is higher than Xencor's net income of -$48.4M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 14.32x while Xencor's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.29x versus 4.57x for Xencor. Usually stocks with elevated PS ratios are considered overvalued.